Clinical Trial Detail

NCT ID NCT02414139
Title Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

non-small cell lung carcinoma

Therapies

Capmatinib

Age Groups: adult

Additional content available in CKB BOOST